Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

Kojiro Sato(Tokyo Medical and Dental University), Ayako Suematsu(Tokyo Medical and Dental University), Kazuo Okamoto(Tokyo Medical and Dental University), Akira Yamaguchi(Graduate School USA), Yasuyuki Morishita, Yuho Kadono(The University of Tokyo), Sakae Tanaka(The University of Tokyo), Tatsuhiko Kodama(The University of Tokyo), Shizuo Akira(The University of Osaka), Yoichiro Iwakura(Tokyo University of Science), Daniel J. Cua, Hiroshi Takayanagi(Tokyo Medical and Dental University)
The Journal of Experimental Medicine
November 6, 2006
Cited by 1,523Open Access
Full Text

Abstract

In autoimmune arthritis, traditionally classified as a T helper (Th) type 1 disease, the activation of T cells results in bone destruction mediated by osteoclasts, but how T cells enhance osteoclastogenesis despite the anti-osteoclastogenic effect of interferon (IFN)-gamma remains to be elucidated. Here, we examine the effect of various Th cell subsets on osteoclastogenesis and identify Th17, a specialized inflammatory subset, as an osteoclastogenic Th cell subset that links T cell activation and bone resorption. The interleukin (IL)-23-IL-17 axis, rather than the IL-12-IFN-gamma axis, is critical not only for the onset phase, but also for the bone destruction phase of autoimmune arthritis. Thus, Th17 is a powerful therapeutic target for the bone destruction associated with T cell activation.


Related Papers

No related papers found

Powered by citation graph analysis